DR. JAI VORA
Skip to content

Weight Loss & GLP-1 · 11 min read

GLP-1 Side Effects: Ozempic, Wegovy and Mounjaro Side Effects Explained by a Doctor

Common and serious GLP-1 side effects, Ozempic, Mounjaro and Wegovy side effects compared, muscle loss, nutrient gaps, who should avoid them and how to reduce side effects with food.

Quick answer

The most common GLP-1 side effects are nausea, vomiting, diarrhoea, constipation, bloating and stomach pain, which are worst when starting or increasing the dose. Less common but serious side effects include pancreatitis, gallstones, dehydration with kidney strain, low blood sugar when combined with insulin or sulfonylureas, and worsening diabetic eye disease after rapid sugar drops. Ozempic, Wegovy and Mounjaro share a similar side effect profile. Losing muscle and nutrients during rapid weight loss is another important, often overlooked effect.

Key takeaways

  • Stomach and gut symptoms affect most users at some point; in STEP 1 about 3 in 4 people on semaglutide reported them.
  • Serious risks are uncommon but real: pancreatitis, gallbladder disease, bowel blockage, kidney strain from dehydration.
  • People with a personal or family history of medullary thyroid cancer or MEN2, and pregnant women, should not use these drugs.
  • Slow dose increases, small protein-rich meals, fluids and fibre reduce many side effects.
  • Weight regain after stopping and loss of lean mass are long-term considerations to plan for.

Why GLP-1 drugs cause side effects

GLP-1 drugs slow down how fast the stomach empties and act on brain centres that control appetite and nausea. These are the same actions that make them work — so stomach side effects are expected, not unusual. They tend to be worst in the first weeks and after each dose increase, then settle for many people. For a full comparison with diet-based weight loss, see Ozempic vs natural weight loss.

Common GLP-1 side effects

These are reported by large numbers of people in trials and in the official product information:

  • Nausea — the most common side effect, especially after large or fatty meals.
  • Vomiting and diarrhoea, which can lead to dehydration.
  • Constipation, bloating, burping, wind and stomach pain.
  • Acid reflux and indigestion.
  • Tiredness, dizziness and headache.
  • Injection-site redness or itching.
  • Hair thinning, usually linked to rapid weight loss rather than the drug itself.

Serious and rare side effects

Most people never experience these, but you should know the warning signs and contact a doctor urgently if they appear:

Serious and rare side effects
RiskWhat to watch for
PancreatitisSevere, persistent upper stomach pain that may spread to the back, with or without vomiting
Gallstones and gallbladder inflammationPain in the upper right abdomen, fever, yellow eyes or skin — more likely with rapid weight loss
Bowel obstruction or severe slowing of the stomach (gastroparesis)Persistent vomiting, severe bloating, inability to pass stool or gas
Dehydration and kidney strainVery little urine, dizziness, weakness after vomiting or diarrhoea
Low blood sugar (hypoglycaemia)Shaking, sweating, confusion — mainly if also on insulin or sulfonylurea tablets
Worsening diabetic eye diseaseBlurred or changed vision — linked to rapid sugar lowering in people with existing retinopathy
Allergic reactionSwelling of face or throat, rash, difficulty breathing

Ozempic side effects vs Wegovy side effects vs Mounjaro side effects

Ozempic and Wegovy contain the same medicine (semaglutide), so their side effects are the same; Wegovy uses a higher dose, so stomach symptoms can be more frequent. Mounjaro (tirzepatide) works on GLP-1 and GIP, and its side effects are very similar — mainly nausea, diarrhoea, vomiting, constipation and reduced appetite, rising with dose. In SURMOUNT-1, between about 4% and 7% of people on tirzepatide stopped because of side effects, compared with 2.6% on placebo. In STEP 1, 7% stopped semaglutide for side effects versus 3.1% on placebo.

What large studies found about stomach risks

A 2023 study of health records published in JAMA compared people using GLP-1 drugs for weight loss with people using another weight-loss medicine. GLP-1 users had a higher risk of pancreatitis, bowel obstruction and gastroparesis. The absolute risk for any one person remained low, but it is a reason these medicines should be prescribed and monitored by a doctor, not bought online.

Muscle loss and nutritional deficiencies

Because these drugs cut appetite so sharply, many people eat too little protein, fibre and micronutrients. Body-scan studies show that roughly a quarter to two-fifths of the weight lost can be lean mass, which includes muscle. Low intake can also lead to deficiencies of iron, vitamin B12, vitamin D, calcium and other nutrients, along with constipation from low fibre and fluids. Read GLP-1 muscle loss and how to prevent it.

Long-term considerations

GLP-1 drugs are relatively new for weight management, so experience beyond a few years is still growing. What we know so far:

  • Weight usually returns after stopping: in the STEP 1 extension, two-thirds of lost weight came back within a year.
  • Many people need to stay on treatment long term, with the cost, monitoring and side effects that brings.
  • Rodent studies showed thyroid C-cell tumours; human risk is not established, but the drugs are not used in people with a personal or family history of medullary thyroid cancer or MEN2.
  • Regulators continue to review reports of rare effects; always read the latest product information and tell your doctor about any new symptom.

Who should not take GLP-1 drugs (or needs extra caution)

Discuss these with your doctor before starting:

  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2).
  • Pregnancy, planning pregnancy or breastfeeding — semaglutide should be stopped at least two months before a planned pregnancy.
  • Past pancreatitis or gallbladder disease.
  • Diabetic retinopathy, kidney disease or severe stomach conditions such as gastroparesis.
  • History of eating disorders, or older adults with low muscle mass.
  • Upcoming surgery or endoscopy — tell your anaesthetist, as delayed stomach emptying matters.

How to reduce GLP-1 side effects with food

If you and your doctor decide a GLP-1 medicine is right for you, these simple habits reduce side effects and protect your health:

  • Eat small meals slowly and stop at the first sign of fullness.
  • Make protein the first thing on your plate at every meal (dal, curd, paneer, eggs, fish, chicken, tofu).
  • Avoid large, oily, fried or very spicy meals, especially in the first weeks and after dose increases.
  • Sip water through the day — aim for pale yellow urine — and add buttermilk or nimbu pani without sugar.
  • Increase fibre gradually with cooked vegetables, oats, millets and fruit to prevent constipation.
  • Limit alcohol and sugary drinks, which worsen nausea and low sugar risk.
  • Do strength exercises two or three times a week to protect muscle.

Prefer to lose weight without injections?

Many people would rather avoid these side effects altogether, and for mild to moderate excess weight, prediabetes, PCOS or fatty liver a food-first approach is often the right start. See natural alternatives to Ozempic and how to lose weight without medication, or book an online consultation for a plan built on your own reports with Dr. Jai Vora's cellular nutrition approach.

Frequently asked questions

What are the most common side effects of Ozempic?

Nausea, vomiting, diarrhoea, constipation, stomach pain, bloating and reduced appetite, usually worst when starting or increasing the dose.

What are Mounjaro injection side effects?

Mounjaro side effects are similar to other GLP-1 drugs: nausea, diarrhoea, vomiting, constipation, indigestion and decreased appetite, plus rarer risks such as pancreatitis and gallbladder problems.

Are Wegovy side effects worse than Ozempic?

They contain the same medicine. Wegovy is used at a higher dose (up to 2.4 mg), so stomach side effects can be somewhat more frequent.

Do GLP-1 side effects go away?

For many people, nausea and other stomach symptoms improve after the first few weeks at a steady dose. Persistent or severe symptoms need medical review.

Does Ozempic cause muscle loss?

Part of the weight lost on GLP-1 drugs is lean mass, which includes muscle. Eating enough protein and doing strength training helps protect muscle.

Can diet reduce side effects of Mounjaro or Ozempic?

Yes. Small, slow, protein-first meals, avoiding fried and fatty food, enough fluids and gradual fibre increases reduce nausea and constipation for many people.

100% Virtual Clinical Care Worldwide

Get a cellular nutrition plan built on your own reports

Every consultation and diet plan is handled personally by Dr. Jai Vora, by video call and WhatsApp.

Book an Online ConsultationWhatsApp Dr. Jai

References

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002. Source
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. Source
  3. Sodhi M, et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023;330(18):1795–1797. Source
  4. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834–1844. Source
  5. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. Source
  6. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16–27. Source
  7. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344–367. Source
  8. European Medicines Agency. Ozempic (semaglutide) — EPAR product information. Source
  9. European Medicines Agency. Wegovy (semaglutide) — EPAR product information. Source
  10. European Medicines Agency. Mounjaro (tirzepatide) — EPAR product information. Source
  11. US Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss. Source

This article is for education only. Speak with your doctor before changing medication, diet or treatment.

More from the GLP-1 vs Natural Weight Loss guide

← All articles